EyePoint Pharmaceuticals, Inc. EYPT Cash Flow

Eyepoint pharmaceuticals, inc. (EYPT)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10
Cash flows from operating activities:
Net loss
-13,174	-10,410	-15,647	-11,498	-19,238	-11,594	-33,126	-34,428	-6,978	-	-5,983	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-5,140	-67	-7,162	-	-5,041	-5,186	-4,933	-5,146	-4,998	-4,075	20,566	-3,967	-2,187	-3,514	-3,687	-3,947	-2,794	-2,608	-2,551	-2,262	-2,686	-17,460	-2,427	-140	-2,685	-2,695	-3,108
Adjustments to reconcile net loss to cash flows used in operating activities:
Amortization of intangible assets
615	615	615	615	615	614	615	615	0	184	182	182	179	180	183	187	187	190	192	191	190	193	196	196	196	194	192	191	192	193	193	193	192	819	833	840	829	822	811
Depreciation of property and equipment
33	35	31	34	44	54	43	41	43	44	39	32	27	26	6	64	29	30	29	33	22	22	35	36	35	29	39	57	57	56	55	78	44	44	24	15	15	13	10
Amortization of debt discount
171	166	160	130	140	158	154	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivatives
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	128	42	10	334	458	338
Amortization of bond (discount) premium on marketable securities
-	-	-	-	-	-	-	-	-	-	-	0	-2	-2	-5	1	18	34	34	32	25	23	18	19	2	7	17	29	38	41	44	41	62	76	85	85	38	37	29
Non-cash interest expense
323	324	322	294	112	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of debt
0	0	0	0	-3,810	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation
1,160	857	977	1,496	1,238	1,153	1,397	974	443	606	681	682	644	396	734	614	661	483	405	621	614	417	309	448	441	305	217	399	312	263	343	390	379	165	477	579	574	448	451
Change in fair value of derivative liability
-	-	-	-	-	0	-18,886	-23,953	-2,325	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-13	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable and other current assets
2,320	4,623	0	8,635	2,046	182	529	-8	249	55	-129	-251	87	52	-8	-	236	-384	-136	-	-230	-24,705	25,323	-	-319	-1,154	457	-	432	-163	-147	-	250	168	-206	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	756	-	-135	-525	-972	-	-283	99	-240	-	87	898	-350	-	-9	-5	235	-	475	-870	-438	-	501	286	-2	-	205	-357	-373	-	-	-	-
Inventory
1,221	-421	888	785	607	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-1,944	1,115	-345	1,233	2,593	-960	756	2,793	-134	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets and operating lease liabilities
-3	-1	3	9	35	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
15	15	0	0	-30	30	0	-240	-265	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48	-514	251
Accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109	-243	-303
Deferred revenue
-	-	-	-	-	-	0	-	-265	495	-40	-	120	-3	-8	-	-8	-9	-8	9	-34	-34	-35	23	-1,140	510	340	-103	164	-176	150	-195	-89	-181	-1,430	-558	-21	979	480
Deferred rent
-	-	-	-	-	186	38	-7	-4	-5	-4	-4	-2	-1	-2	0	1	2	2	2	6	5	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-4,543	-5,009	-6,486	-	-4,302	-3,174	-4,493	-3,006	-3,954	21,251	-3,994	-2,785	-1,852	-2,257	-3,777	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-16,345	-11,486	-14,772	-17,107	-13,334	-10,820	-11,766	-6,082	-4,819	-	-5,968	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,782	-1,621	-	-2,143	-2,360	-2,660	1,245	-1,613	-583	-2,219
Cash flows from investing activities:
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	0	-1	3,000	2,053	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,399	3,308	2,535	-	5,390	3,036	251	-	-	-	-	0	3,173	1,786	2,799	3,154	5,323	3,184	3,731	5,030	4,905	2,562	3,466
Maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,863	3,305	2,000	-	2,650	0	250	0	500	1,400	1,450	-	-	-	-	-	-	-	-	-	-	-	-
Maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	2,500	3,350	5,393	7,500	-	-	-	-	-	-	-	-	-	-	-	-	-	3,746	4,688	3,450	-	5,450	3,199	3,400	3,489	2,359	450	300
Acquisition of Icon Bioscience Inc., net of cash acquired
-	-	-	-	-	-	0	1,708	15,072	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
16	6	0	25	182	23	109	45	-1	0	64	126	16	5	0	46	31	25	11	90	43	22	6	173	54	13	8	19	13	32	4	6	19	159	221	65	9	50	9
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	0	0	0	33	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash (used in) provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	3,335	2,388	5,480	-	1,433	-28	-546	-885	-2,783	-3,058	-7	-421	-2,264	1,309	1,442	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in investing activities
-16	-6	0	-25	-182	-23	-109	-1,752	-15,072	-	-64	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,870	647	-	108	959	-552	-1,606	-2,555	-2,162	-3,175
Cash flows from financing activities:
Proceeds from exercise of warrants
-	-	-	-	-	0	28,863	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of stock, net of issuance costs
20,285	-	-	-	-	-	0	25,205	9,266	6,081	963	6,099	2,305	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of long-term debt
-	0	0	15,000	35,000	-	0	5,000	15,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of debt issue costs
-	0	0	447	894	-	0	442	905	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of long-term debt principal
-	0	0	0	20,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of extinguishment of debt costs
-	0	0	0	2,716	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net settlement of stock units to satisfy statutory tax withholding
19	33	41	26	20	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and employee stock purchase plan
187	-	-	-	264	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on finance lease obligations
7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,005	1,163	9,981	0	0	-66	4,735	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	0	90	0	9	132	20	329	9	0	0	179	56	-	-	-	-	-	-	-	-	0	0	0	114	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	2,395	0	9	-	16,530	329	9	0	0	179	56	-14	7,457	1,620	9,981	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
20,446	1,945	2,371	17,914	11,634	341	28,863	30,266	23,361	-	963	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-66	4,735	-	0	0	114	-	-	-	-
Effect of foreign exchange rate changes on cash and cash equivalents
0	1	0	0	0	-1	0	-	-	-	4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net increase (decrease) in cash, cash equivalents and restricted cash
4,085	-9,546	-12,401	782	-1,882	-10,503	16,988	22,430	3,470	-	-5,065	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of foreign exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-1	-2	-8	-	-4	-5	-3	5	-7	-5	-5	-1	-5	1	1	0	-9	-1	2	-3	2	-2	-3	-2	6	-4	6
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	1,186	-2,623	-1,005	-	13,657	-2,878	-5,033	-3,886	-6,744	18,367	-3,950	-3,221	3,336	673	7,647	-1,099	-1,411	1,021	3,763	-1,750	-2,033	-1,403	-3,101	-384	5,919	-2,749	-5,388
Supplemental cash flow information:
Cash interest paid
1,290	1,296	2,399	64	1,111	658	583	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-44	50	50
Supplemental disclosure of non-cash investing and financing activities:
Stock issuance costs
295	-	-	-	-	-	-	-	143	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock issuance costs
295	-	-	-	-	-	-	-	143	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt issue costs
-	-	-	-	222	-	-	-	307	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued acquisition costs
-	-	-	-	-	-	-	-	1,737	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued development milestone
-	-	-	-	-	-	0	0	15,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued term loan exit fee
-	0	0	900	2,100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Principal portion of finance lease liabilities
7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of second tranche purchase liability
-	-	-	-	-	-	0	0	4,734	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of warrants issued with debt
-	-	-	-	-	-	0	-5	360	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	88	-	-	-	-
Stock issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	67	-	-	-	-	-	-	-	-